Automated Insulin Delivery in T1D and glucagon secretion
Research type
Research Study
Full title
Can Maximising Time-in-Range using Automated Insulin Delivery and a Low Carbohydrate Diet Restore The Glucagon Secretion To Hypoglycaemia in Type 1 Diabetes?
IRAS ID
274075
Contact name
Shareen Forbes
Contact email
Sponsor organisation
University of Edinburgh
Clinicaltrials.gov Identifier
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
2 years, 4 months, 14 days
Research summary
Almost all people who have had type 1 diabetes for 5 years have a defect in secretion of the hormone Glucagon. This hormone is involved in the body's response to low blood glucose (hypoglycaemia). It works by releasing glucose stores from the liver. This defect therefore increases the risk of severe hypoglycaemia. The reason for this Glucagon defect in people with Type 1 diabetes is currently unknown.
A previous study using mouse models showed that good blood glucose control restored alpha cell function, the cell that produces Glucagon in the pancreas, however no other studies have been done in humans.
This study aims to look at the Glucagon response to hypoglycaemia in 24 people with type 1 diabetes to ascertain whether tight blood glucose control over a period of time improves this response.
We aim to achieve good blood glucose control using new generation Automated Insulin Delivery systems (AIDs). This system is made of: an insulin pump, a continuous glucose monitor (CGM) and an algorithm that allows adjustment of insulin delivery based on CGM readings. This is the most up to date technology that there is in the management of type 1 diabetes. To ensure a very good blood glucose control participants will also follow a low carbohydrate diet. The Glucagon response to low blood glucose will be measured at zero and eight months.REC name
South East Scotland REC 01
REC reference
20/SS/0117
Date of REC Opinion
18 Nov 2020
REC opinion
Further Information Favourable Opinion